Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...

Listen and subscribe to Stocks In Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcast.Nvidia’s (NVDA) explosive growth is doing more than lifting portfolios - it’s ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

Core earnings per share, which excludes nonrecurring items, fell to $2.12 from $3.59 in the same period a year ago, but above the average analyst estimate compiled by FactSet of $2.03.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Patients with migraine spontaneously described typical symptoms like pain but only revealed cognitive symptoms after being asked further questions, according to a speaker at the American Headache ...